Background: Warfarin has very narrow therapeutic windows and large individual variability. Genetic variants encoding VKORC1 gene has resulted in altered sensitivity to warfarin or warfarin resistance. Nine haplotypes (H1-H9) of VKORC1 had been categorized with reference to 10 SNPs (Gen Bank accession number AY587020). Objective: To determine the haplotypes frequencies of VKORC1 gene among the patients prescribed warfarin and to correlate the dose, INR and bleeding with haplotypes. Method: A total of 158 patients prescribed warfarin and met the inclusion criteria were recruited after informed consent. Five ml of blood was drawn from each patient and DNA was extracted for genotyping of VKORC1 variants. Two steps PCR methods were developed t...
Warfarin is a widely used anticoagulant that has a narrow therapeutic range because of both genetic ...
It was aimed to underline the importance and explain the meaning of genetic testing in warfarin dosi...
Patients require different warfarin dosages to achieve the target therapeutic anticoagulation. The v...
Background: Warfarin has very narrow therapeutic windows and large individual variability. Genetic v...
Polymorphisms in vitamin K epoxide reductase complex subunit 1 (VKORC1) gene lead to interindividual...
Warfarin is an anticoagulant prescribed in the treatment and prevention of thrombosis. Variation in ...
Warfarin is a commonly-prescribed anticoagulant used to treat and prevent thromboembolic events. The...
Objective: Warfarin is the most commonly prescribed oral anticoagulant, although having a narrow the...
AbstractWarfarin is a commonly prescribed oral anticoagulant used for prophylaxis and treatment of d...
What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reduct...
Objective: Genetic polymorphisms of CYP2C9 and VKORC1 play major role in pharmacokinetics and pharma...
Polymorphisms in CYP 2C9 and VKOR C1 have been shown to be associated with warfarin dose requirement...
OBJECTIVE To systematically review evidence on genetic variants influencing outcomes during warfa...
Background: Warfarin is the most widely used oral anticoagulant for the prevention and treatment of ...
Genetic testing for common variants in the CYP2C9 and VKORC1 genes may provide useful clinical infor...
Warfarin is a widely used anticoagulant that has a narrow therapeutic range because of both genetic ...
It was aimed to underline the importance and explain the meaning of genetic testing in warfarin dosi...
Patients require different warfarin dosages to achieve the target therapeutic anticoagulation. The v...
Background: Warfarin has very narrow therapeutic windows and large individual variability. Genetic v...
Polymorphisms in vitamin K epoxide reductase complex subunit 1 (VKORC1) gene lead to interindividual...
Warfarin is an anticoagulant prescribed in the treatment and prevention of thrombosis. Variation in ...
Warfarin is a commonly-prescribed anticoagulant used to treat and prevent thromboembolic events. The...
Objective: Warfarin is the most commonly prescribed oral anticoagulant, although having a narrow the...
AbstractWarfarin is a commonly prescribed oral anticoagulant used for prophylaxis and treatment of d...
What is known and Objectives: Testing for cytochrome P450-2C9 (CYP2C9) and vitamin K epoxide reduct...
Objective: Genetic polymorphisms of CYP2C9 and VKORC1 play major role in pharmacokinetics and pharma...
Polymorphisms in CYP 2C9 and VKOR C1 have been shown to be associated with warfarin dose requirement...
OBJECTIVE To systematically review evidence on genetic variants influencing outcomes during warfa...
Background: Warfarin is the most widely used oral anticoagulant for the prevention and treatment of ...
Genetic testing for common variants in the CYP2C9 and VKORC1 genes may provide useful clinical infor...
Warfarin is a widely used anticoagulant that has a narrow therapeutic range because of both genetic ...
It was aimed to underline the importance and explain the meaning of genetic testing in warfarin dosi...
Patients require different warfarin dosages to achieve the target therapeutic anticoagulation. The v...